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Abstract 
 
Previous researchers have postulated that gastrointestinal bacteria may 
contribute to the development and maintenance of Autism Spectrum Disorders 
(ASD). There is evidence based on quantitative evaluation of the 
gastrointestinal bacterial population in ASD that this is unlikely and an 
alternate mechanism will be examined where the bacteria may contribute to 
the development of ASD via their metabolic products and the role of biogenic 
amines (BAs) will be investigated. In humans, BAs influence a number of 
physiological processes via their actions as neurotransmitters, local hormones 
and gastric acid secretion. Various amines have been implicated in several 
medical conditions such as schizophrenia and colon cancer. To date, the 
relationship between BAs and autism has not been explored. This study has 
been designed to identify differences (and/or similarities) in the level of BAs 
in faecal samples of autistic children (without gastrointestinal dysfunction: n = 
14; with gastrointestinal dysfunction; n = 21) and their neurotypical siblings (n 
= 35) by LC-MS/MS. Regardless of the diagnosis, severity of ASD and 
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gastrointestinal dysfunction there were no significant differences found 
between the groups. The findings suggest that BAs in the gastrointestinal tract 
do not play a role in the pathophysiology of gastrointestinal dysfunction 
associated with ASD. 
 
Keywords: Autism, ASD, biogenic amines, faecal, chromatography.  
 
 
Introduction 
Biogenic amines (BAs) are low molecular weight nitrogenous compounds mainly 
formed and degraded as part of the normal metabolism of animals, plants and 
microorganisms by decarboxylation of amino acids or by amination and 
transamination of aldehydes and ketones [1]. The basic structure of BAs can be 
aromatic (tyramine, phenylethylamine), aliphatic (putrescine, cadaverine, spermine, 
spermidine) or heterocyclic (histamine, tryptamine). In humans, BAs play a number 
of physiological roles by acting as neurotransmitters and local hormones [2]. BAs are 
involved in gastric acid secretion; cell growth and differentiation; they are required 
for the synthesis of DNA, RNA, and proteins; are involved in the regulation of 
circadian rhythm; maintenance of body temperature; food intake; learning and 
memory; immune response and allergic reactions [3; 4; 5]. An essential factor in the 
formation of BAs in food products and the gastrointestinal (GI) tract is the presence of 
bacterial strains with the capacity to decarboxylate amino acids. This ability has been 
described in different genera, species and strains of bacteria, both Gram positive and 
Gram negative. Amino acid decarboxylases are found in certain Enterobacteriaceae, 
Clostridium, Lactobacillus, Streptococcus, Micrococcus and Pseudomonas species, 
among others [6].  
 The concentrations of BAs present in cells and tissues are strongly controlled at 
the stages of catabolism, biosynthesis, uptake and efflux, however, the ingestion of 
foods rich in BAs or production in the intestine by intestinal microbiota can alter the 
equilibrium [7; 8]. Various BAs have been associated with migraine, schizophrenia, 
colon cancer and the onset of hypertensive symptoms [4; 9; 10; 11; 12], however, a 
link between BAs and Autism Spectrum Disorder (ASD) has not been explored 
despite many researchers suggesting that gastrointestinal bacteria contribute to the 
development of ASD [13; 14]. 
 ASDs are defined by cognitive defects, impairments of spoken and/or receptive 
language and social interactions as well as repetitive and stereotyped behaviours. In 
addition to these core deficits, previous studies have indicated that the prevalence of 
gastrointestinal distress is high in individuals with ASD [15; 16; 17; 18; 19]. The 
percentage of individuals suffering from GI problems varies from study to study, but 
high rates of GI dysfunction in individuals with ASD have been reported in several 
studies with symptoms including abdominal pain, constipation, diarrhoea, alternating 
diarrhoea and constipation as well as GI inflammation [20; 21; 22]. 
 In a previous study, we noted that not all ASD individuals suffered from GI 
dysfunction and that only a sub-population were affected. We also noted that only a 
subset of this GI dysfunction group had unusual bacterial populations, which included 
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very high and very low numbers of beneficial bacteria and similarly harmful bacteria, 
regardless of severity and GI dysfunction [18]. In a subsequent study, we failed to 
find any significant differences in the microbiome of ASD children (with and without 
GI dysfunction) and their neurotypical siblings (with and without GI dysfunction) 
[23], however, given that GI distress is a commonly reported symptom in ASD 
children, we have designed this follow up study to consider other possible factors that 
may contribute to GI dysfunction. Therefore, we evaluated BAs which can be 
produced by microbiota [24] or ingested from food rich in BAs and directly absorbed 
through the intestinal epithelium. High quantities of tyramine and histamine have 
been associated with GI symptoms including nausea, abdominal cramping and 
diarrhoea. Tyramine has been proposed as an initiator of hypertensive crisis [3]. The 
toxicity of histamine appears to be enhanced by the presence of other amines such as 
cadaverine, putrescine and tyramine. These biologically active amines have important 
physiological effects in humans, generally either psychoactive or vasoactive [25]. All 
have been shown to be involved in the central nervous system responses to stress [26]. 
BAs also act as releasing agents for the neurotransmitters and abnormally low 
physiological concentrations often result in clinical depression, whereas abnormally 
high concentrations have a strong correlation with schizophrenia [27; 28]. To date, no 
research has evaluated the role of BAs in the GI symptoms of autistic children even 
though there is good evidence those BAs can influence neurological processes. 
 Analytical methods for BAs in faecal samples involve high performance liquid 
chromatography (HPLC). Most biogenic amines require derivatisation to be detected 
by a UV-Visible or fluorescence detector in HPLC.  Therefore, liquid 
chromatography mass spectrometry (LC-MS) is extensively used for their direct 
analysis. With LC-MS, the derivatisation step can be avoided and sample processing 
time can be reduced which is important when a large number of samples are to be 
analysed. However, LC-MS is often affected by matrix effects where both ion 
enhancement and suppression have been observed with suggested strategies available 
if they are apparent [2]. Therefore, the method development process needs to 
investigate this possibility with faecal samples being a relatively unique matrix 
compared to other biological matrices such as urine, blood and saliva. 
 In this study, we have developed a method for the detection of the seven biogenic 
amines in faecal samples. In this method, amines were extracted with aqueous 
trichloroacetic acid (TCA), separated by liquid chromatography and detection was 
achieved by positive ionisation with a triple quadrupole mass spectrometer operating 
in multiple-reaction monitoring (MRM) mode. This method was applied to a range of 
faecal samples obtained to identify differences (and/or similarities) in the biogenic 
amines in children with autism. 
 
 
2. Experimental 
2.1 Sample collection 
The study was approved by the Human Research Ethics Committee of Swinburne 
University of Technology, Australia. Participants were recruited through notices 
posted on websites and newsletters of various local state and national bodies related to 
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autism (Autism Victoria, Autism South Australia, Autism Spectrum Australia and 
Autism Australian Capital Territory), autism schools in Victoria (Wantirna Heights 
School, Southern Autistic School, Western Autism School, Northern School for 
Autism, Mansfield Autism Statewide Services) and New South Wales (Aspect Central 
Coast School, Aspect Hunter School, Aspect South Coast School, Aspect South East 
Sydney School, Aspect Vern Barnett School and Aspect Western Sydney School). 
 
2.2 Protocol 
1. The study was explained to parents and informed consent received. 
2. Parents filled out a questionnaire relating to socio-demographic variables and 
their children’s diagnosis and symptoms (including GI). 
3. Stool samples were collected by parents in sterilized faecal sample collection 
containers during March -June 2011 and transported to Swinburne University 
in a 1-day express air post satchel containing a frozen gel-iced pack.  
 
 Seventy children (n = 35 with ASD and n = 35 neurotypical siblings) with an age 
range of 2 to 12 years participated in this study (see Table 1 for participant 
characteristics). The autism severity category was based on CARS (Childhood Autism 
Rating Scale) assessment conducted by registered psychiatrists or psychologists as 
reported by the parents of participants. Existing assessments were used; with no 
confirmatory assessment being conducted. In Australia, formal assessment and re-
assessment of Autism and Asperger’s disorder occurs annually as part of the 
requirements of the educational and social services systems. Therefore, we can 
assume that the assessments were current to within 12 months. The GI dysfunction 
criteria included one or more of the following listed symptoms: constipation; 
diarrhoea; abdominal discomfort or pain; gaseousness; foul-smelling stools.  
 
2.3 Reagents and standards 
Ultra-pure water from a Millipore Milli-Q system (Milford, MA, USA) was used for 
the preparation of all the solutions. Trichloroacetic acid (TCA) (≥99%), cadaverine 
dihydrochloride (>99%), histamine dihydrochloride (>99%), spermidine 
trihydrochloride (>99.5%), tryptamine hydrochloride (99%), tyramine hydrochloride 
(99%), agmatine sulphate (≥97%), ammonium formate and formic acid (≥95%) were 
acquired from Sigma–Aldrich, whereas acetonitrile was obtained from Merck. 
 A 30mM ammonium formate buffer (pH 4) was prepared and the pH was adjusted 
with formic acid. Standard solutions of biogenic amines were prepared in Milli-Q 
water and kept in 2 mL aliquots in plastic vials at −20°C. When required, these were 
brought to 25°C before preparation of more diluted solutions in 2% TCA each day. A 
fresh standard mixture of all seven amines (1 mg/mL) was prepared and further 
diluted for calibration. 
 
2.4 Extraction of biogenic amines 
Two millilitres of 10% TCA was added to 1 g of faecal matter that was contained in a 
15 mL Falcon tube. The mixture was homogenized by vortex mixing for 1 min, 8 mL 
of Milli-Q water was added and the mixture was incubated for 30 mins at 4°C. The 
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mixture was filtered through a Whatman no. 1 filter paper using a vacuum system. 
The extraction process was carried out on ice to minimise the loss of the more volatile 
amines. The filter was washed three times by adding 5 mL of 2% TCA each time and 
the final volume was adjusted to 25 mL with 2% TCA. This solution was filtered 
through a 0.45 m nylon syringe filter and stored at −20°C until required for analysis. 
 
2.5 Analysis conditions 
Analyses were performed with an Agilent 6410 Triple Quadrupole LC/MS system 
(Agilent Technologies Inc.). Chromatographic separation was developed on a Luna® 
5 µm NH2 100 Å (250×3.0 mm) (Phenomenex, NSW, Australia). Isocratic elution 
with 30mM ammonium formate adjusted to pH 4 with formic acid and acetonitrile in 
a ratio of 3:1 was used with a flow rate of 0.5 mL/min and the injection volume was 
50 μL. Quantitation of the amines was based on the fragmentation transitions MRM 
mode as listed in Table 2. The ESI probe tip was 3.5 kV, nitrogen was used as the 
nebulizer gas and heated to 300°C at 15 psi, and the insource fragmenting voltage was 
35 V for putrescine and 70 V for the other amines. 
 
2.6 Statistical analysis 
A one-way ANOVA and independent sample t-test were conducted to compare 
amines between the groups based on ASD severity and GI dysfunction. Statistical 
significance was defined as a p value of less than 0.05 with BA concentration data 
presented as means with standard deviations. In addition, Principal Component 
Analysis (PCA) was performed to further explore if there were any influential factors. 
All statistical analyses were performed using Statistical Package for Social Sciences 
(SPSS) for Windows Statistical Package Version 19.0. 
 
 
3. Method validations 
3.1 Linearity 
The linearity of the method for each amine was determined from data collected for six 
different concentrations of biogenic amines in mixtures ranging from 0.05 - 10 mg/L, 
using triplicate injections for each mixture of different concentrations. Calibration 
graphs for each amine were constructed by plotting the peak-area against the amine 
concentration and the correlation coefficient is listed in Table 2. The correlation 
coefficients indicate that good linearity exists for the range of concentrations tested, 
which is also given in Table 2. 
 
3.2 Limits of detection and quantification 
The limits of detection (LOD) were calculated from the concentration of amines 
required to give a signal-to-noise ratio of 3. The limits of quantification (LOQ) were 
determined with a signal-to-noise ratio of 10. Both LOD and LOQ are presented in 
Table 2. 
 
3.3 Matrix effect 
To study the effect of the matrix, 10 mL of faecal extract from the extraction 
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procedure described in section 2.4 was spiked with a known amount of standard 
mixture of amines. The faecal extract contained some amines and the areas for the 
spiked samples were corrected by subtraction (the results of this analysis were 
compared with a set of external standard mixtures using a four-point calibration curve 
- 0.5, 1, 2.5, 5 μg/mL prepared in the 2% TCA). Matrix effect (ME) values were 
calculated according to the following formula [29]. 
 %100 x 1




 
A
BME  (1) 
 
Where, A is the peak area for the external standards and B is the peak area from the 
spiked faecal samples. The values in Table 2 indicate that significant and varied ion 
suppression prevents the use the external standards as prepared in section 2.3 and that 
standardisation requires the use of standards prepared using spiked faecal samples. 
 
3.4 Recovery 
The overall recovery of the sample preparation process as described in section 2.4 was 
determined by spiking 1 g of faecal sample with a known amount of standard mixture 
of seven amines in three replicates. Once again the amount of amines initially present 
was subtracted from the spiked samples. It can be seen from Table 2 that the recovery 
of amines from the extraction process is quantitative but considering the matrix 
effects previously described, it has not totally eliminated components from the faeces 
that influence the ionisation process for the amines. However, the quantitative 
recovery indicates that linearity is maintained in the sample matrix and 
standardisation is possible using standards prepared in the faecal matrix. 
Consequently single point standardisation (2 μg/mL) was used for the samples.  
 
3.5 Final Protocol 
The final optimised method was as follows: Sample prepared as specified in section 
2.4 and were analysed under condition described in section 2.5. The concentration of 
the each compound was calculated based on single point standard (2 μg/mL) prepared 
in the faecal matrix. 
 
 
Results and discussion 
Participants were divided into two groups: those with moderate to severe ASD (n = 
19) and those with mild ASD (n = 16) (Table 1). The severity category was based on 
CARS assessments conducted by registered psychiatrists or psychologists and the 
child’s score reported by parents of participants. CARS scores of less than 37 are 
considered mild and those at or above 37 are considered moderate – severe [30]. 
Details of the specific amine concentrations are given in Table 3 with all 
concentrations being based on the weight of the wet faecal sample. Analyses of 
variance revealed no significant differences between the ASD severity groups and the 
sibling controls on mean levels of all analytes (Table 3). Furthermore, no relationships 
for the biogenic amines were evident between the GI dysfunction and GI normal 
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group (Table 4). However, PCA reveals correlation between GI dysfunction and 
severity (correlation coefficient 0.578). In autism group, 39% of participants with 
severe autism and 61% with mild autism suffered from GI dysfunctions compare to 
2.8% in sibling control participants. Similar to ANOVA, no correlation was found 
between any of the biogenic amines, autism severity and GI dysfunctions. However, 
interestingly there was a correlation between histamine and cadaverine (correlation 
coefficient 0.807).  It has been observed that the presence of cadaverine potentiates 
the biological activity of histamine in laboratory animals [31] most likely due to 
increasing the histamine transport across the gastrointestinal wall [32; 33].  
 Several researchers have hypothesized that the numbers and the species of several 
GI bacteria such as the Clostridium group, Ruminococcus and Deslufovibrio may 
contribute to the development of ASD [13; 14; 34]. However, this hypothesis has little 
consistency with other studies suggesting no significant difference in the bacterial 
count in the autistic individuals and their neurotypical siblings [13; 17; 23; 35]. By 
contrast, this study was designed to evaluate the level of BAs in autistic children and 
determine whether BAs have any possible role in the GI dysfunction associated with 
autistic disorder. The comparison of BAs in autistic children, with and without GI 
dysfunction, and comparison of these children with their neurotypical siblings (again, 
with and without GI dysfunction) did not reveal any significant differences, which 
suggest that BAs in the GI tract may not play a significant role in the pathophysiology 
of GI dysfunction associated with ASD. This follow-up study is consistent with our 
previous study which did not support the hypothesis of a GI bacterial 
pathophysiological mechanism triggering or maintaining ASD [23] as there were no 
significant differences in the bacterial composition of faecal material of our paediatric 
autistic group and their neurotypical siblings.  
 
Table 1 Summary of participant’s characteristic 
 
Participant characteristic Subcategory Autism 
(n=35) 
Neurotypical  
sibling 
(n=35) 
Gender Male 28 10 
 Female 7 25 
Age (years) All subjects 2-12 2-12 
Severity Moderate-Severe 22 NA 
 Mild 13 NA 
Current GI dysfunction, GI dysfunction 21 2 
 Constipation 9 2 
 Diarrhoea 4 0 
 Abdominal Pain 3 0 
 Gaseousness 5 1 
 Foul-smelling stool 9 2 
 No GI dysfunction 14 33 
Past history of GI dysfunction  7 7 
Medically diagnosed GI disorder All subjects 5 2 
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Current oral antibiotic All subjects 0 0 
Current probiotics All subjects 12 4 
Other supplements Fish oil 9 5 
 Multivitamins 10 8 
 Laxative 2 0 
Food allergy1 All subjects 15 4 
Immunization2 Immunization 35 31 
1Gluten, casein, dairy, lactose or preservative free. NA, not available. 
2Australian standard immunization schedule according to age. 
 
 
Table 2 Method validation values of biogenic amines for LC-MS/MS 
 
Biogenic 
amine 
Fragmentation 
transitions (m/z) 
LOD 
(µg/L) 
LOQ 
(µg/L) 
Linearity 
(mg/L) 
R2 ME 
(%) 
Recovery 
(%) 
Spermidine 146.2 to 72.2 20 50 0.02-5 0.9966 
 
-25±4 97±3 
Tryptamine 144.0 to 117.2 25 85 0.025-5 0.9956 
 
-30±3 94±1 
Tyramine 138.1 to 121.1 20 50 0.02-5 0.9992 
 
-24±4 98±8 
Agmatine 131.1 to 114.1 30 100 0.03-5 0.9965 
 
-17±5 105±14 
Histamine 112.1 to 95.0 50 150 0.05-2.5 0.9997 
 
-11±3 105±10 
Cadaverine 103.2 to 86.2 500 1500 0.5-5 0.9947 
 
-28±1 100±2 
Putrescine 89.2 to 72.2 500 1500 0.5-2.5 0.9972 
 
-30±3 100±8 
 
 
Table 3 Mean values of biogenic amines (mg) examined per gram of faecal sample 
for different groups (mild and severe) of ASD individuals and sibling controlwith the 
associated ANOVA based p-value.  
 
Biogenic Amines Control (n=35) Mild (n=16) Severe (n=19) p-value 
Mean Std. dev Mean Std. dev Mean Std. dev 
Spermidine 4.11 1.94 3.64 2.23 4.48 1.79 .463 
Tryptamine 0.16 0.44 0.04 0.16 0.16 0.44 .269 
Tyramine 0.09 0.21 0.18 0.61 0.31 0.69 .282 
Agmatine 2.45 6.65 1.08 2.34 1.37 1.58 .588 
Histamine 0.04 0.13 0.06 0.25 0.15 0.56 .516 
Cadaverine 2.46 3.03 1.87 2.12 4.29 7.35 .236 
Putrescine 5.41 7.24 4.84 8.29 3.96 4.62 .761 
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Table 4 Mean values of biogenic amines (mg) examined per gram of faecal sample 
for different groups (GI dysfunction and No GI dysfunction) of ASD individuals with 
the associated ANOVA based p-value.  
 
Biogenic Amines Autism (n=35) p-value 
GI dysfunction (n=21) No GI dysfunction (n=14)  
Mean Std. dev Mean Std.dev 
Spermidine 3.88 1.97 4.44 2.11 .428 
Tryptamine 0.10 0.38 0.10 0.26 .990 
Tyramine 0.16 0.38 0.41 0.91 .271 
Agmatine 1.15 1.47 1.39 2.55 .728 
Histamine 0.18 0.58 0.00 0.00 .257 
Cadavarine 4.37 7.03 1.40 1.43 .131 
Putrescine 3.76 6.08 5.27 7.14 .505 
 
 
Conclusions 
We have demonstrated that the LC-MS/MS analysis technique can be used with direct 
sample extraction and this decreases the sample processing time, which is desirable 
for BAs analysis as they are very unstable. Furthermore, the reproducibility of the 
analytical results is greatly improved due to automation. The recommended technique 
can be easily integrated into future research assessing BAs in clinical samples 
amongst a larger sample size. 
 The findings of our present study revealed no significant differences between the 
ASD severity groups and the sibling controls. Furthermore, no relationships were 
evident between the GI dysfunction and GI normal group. Therefore, this suggests 
that BAs may not play a significant role in the pathophysiology of ASD. 
Nevertheless, further research is warranted to investigate BAs in the other body fluids 
and tissues before the role of BAs in ASD is ruled out. 
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